STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 2/ Line 73	Abstract/ Methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2/ Lines 73-88	Abstract/ Methods and Results
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4/ Lines 100-132	Introduction/ Paragraphs 1-5
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5/ Lines 133-135	Introduction/ Paragraph 6
Methods				
Study design	4	Present key elements of study design early in the paper	Page 5/ Line 144	Material and Methods/ Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5/ Lines 142-143	Material and Methods/ Paragraph 1
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 5/ Lines 144-155	Material and Methods/ Paragraph 1
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	Not Relevant: we did not perform matched studies	Not Relevant: we did not perform matched studies
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5/ Lines 156-173	Material and Methods/ Paragraphs 3-6

Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	1) Page 6/ Line 173 2) Page 7/ Lines 202-225	1) Material and Methods/ Paragraph 7 2) Material and Methods/ Paragraphs 13-16
Bias	9	Describe any efforts to address potential sources of bias	Page 8/ Line 230	Material and Methods/ Paragraph 18
Study size	10	Explain how the study size was arrived at	Page 8/ Line 255 (Figure 2)	Results/ Paragraph 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 8/ Lines 235-239	Material and Methods/ Paragraph 21
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 8 / Lines 235-250	Material and Methods/ Paragraph 20
		(b) Describe any methods used to examine subgroups and interactions	Not Relevant: we did not use subgroups	Not Relevant: we did not use subgroups
		(c) Explain how missing data were addressed	Page 8/ Lines 239-250	Material and Methods/ Paragraph 21
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Not Relevant: none of these criteria was applicable	Not Relevant: none of these criteria was applicable
		(e) Describe any sensitivity analyses	Not Relevant: we did not use sensitivity analyses	Not Relevant: we did not use sensitivity analyses
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 8/ Line 255 (Figure 2)	Results/ Paragraph 1

		(b) Give reasons for non-participation at each stage	Page 8/ Line 255 (Figure 2)	Results/ Paragraph 1
		(c) Consider use of a flow diagram	Page 8/ Line 255 (Figure 2)	Results/ Paragraph 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 8/ Lines 254-275 (Table 1)	Results/ Paragraph 1
		(b) Indicate number of participants with missing data for each variable of interest	Page 10/ Lines 316-317 (In Tables 3, 4 and 5, number of participants with missing data are represented by 230-N)	Results/ Paragraphs 1-6
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Page 10/ Line 313	Results/ Paragraph 12
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Page 8/ Lines 279-309	Results/ Paragraphs 7-10
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	Not Relevant: we did not use this methodology	Not Relevant: we did not use this methodology
		Cross-sectional study—Report numbers of outcome events or summary measures	Not Relevant: we did not use this methodology	Not Relevant: we did not use this methodology
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 10/ Line 316 (Table 3)	Results/ Paragraphs 11-13
		(b) Report category boundaries when continuous variables were categorized	Page 10/ Line 317 (Tables 4 and 5)	Results/ Paragraphs 11-13
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not Relevant: we did not use this methodology	Not Relevant: we did not use this methodology

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not Relevant: no other analyses were carried out	Not Relevant: no other analyses were carried out
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 10/ Lines 327-329	Discussion/ Paragraph 2
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 13/ Lines 427-443	Discussion/ Paragraph 23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 13/ Lines 427-447	Discussion/ Paragraphs 23-24
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 10/ Lines 324-423	Discussion/ Paragraphs 1-22
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 15/ Line 478	Aknowledgments/ Funding

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org

Article information:https://dx.doi.org/10.21037/qims-22-184
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.